Steroids? Antibiotics? Biologics? Immunomodulators? What Are the Optimal Discharge Medications for an IBD Flare?

  • Jonathan Wagner
  • Daniel EumEmail author


Inflammatory bowel disease flare presentations can be variable. Some patients present with mild complaints and simply need their prior medication regimens restarted, while others may present in septic shock requiring fluid resuscitation, admission for intravenous antibiotics, and possible surgical evaluation. Others will present somewhere in between—they can be safely discharged, but their medication regimens are not ideal. This chapter discusses medications that may improve the likelihood of successful outpatient management.


Inflammatory bowel disease Ulcerative colitis Crohn’s disease Emergency department Antibiotics Immunomodulators Biologics Steroids Mesalamine 5-ASA 


  1. 1.
    Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2015;12(4):205–17.CrossRefGoogle Scholar
  2. 2.
    Chang S, Hanauer S. Optimizing pharmacologic management of inflammatory bowel disease. Expert Rev Clin Pharmacol. 2017;10(6):595–607.CrossRefGoogle Scholar
  3. 3.
    Ford AC, Khan KJ, Achkar J, Moayyedi P. Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2012;107(2):176. author reply 177.Google Scholar
  4. 4.
    Moja L, Danese S, Fiorino G, Del Giovane C, Bonovas S. Systematic review with network meta-analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn’s disease. Aliment Pharmacol Ther. 2015;41(11):1055–65.CrossRefGoogle Scholar
  5. 5.
    Ford AC, Bernstein CN, Khan KJ, Abreu MT, Marshall JK, Talley NJ, et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):599. quiz 600Google Scholar
  6. 6.
    Khan KJ, Ullman TA, Ford AC, Abreu MT, Abadir A, Abadir A, et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):661–73.CrossRefGoogle Scholar
  7. 7.
    Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–76.CrossRefGoogle Scholar
  8. 8.
    Sandborn WJ, van Assche G, Reinisch W, Colombel J, D'Haens G, Wolf DC, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142(2):265.e3.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Keck School of Medicine of the University of Southern California, Los Angeles County/ University of Southern California (LAC+USC) Department of Emergency MedicineLos AngelesUSA

Personalised recommendations